Why tyrosinase for treatment of melanoma.

Lancet (London, England) ·Vol. 350 ·No. 9071 ·1997-07-12 ·Pages 82-3

Song YH

Abstract

暂无摘要

MeSH Terms

Animals Antigens, Differentiation/analysis Autoantigens/analysis Autoimmune Diseases/immunology CD4-Positive T-Lymphocytes/immunology CD8-Positive T-Lymphocytes/immunology Disease Models, Animal Humans Lymphocyte Activation/immunology Melanocytes/immunology Melanoma/complications,drug therapy,immunology Mice Mice, Inbred C57BL Monophenol Monooxygenase/immunology,therapeutic use Skin Neoplasms/complications,drug therapy,immunology Vitiligo/complications,immunology

Chemicals

Antigens, Differentiation Autoantigens Monophenol Monooxygenase

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Song Y H

Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville 32610-0275, USA.

Article Info

Journal

Lancet (London, England)

Abbr.

Lancet

ISSN

0140-6736

DOI

10.1016/S0140-6736(05)61810-7

Published

1997-07-12

Pages

82-3

Language

English

Region

England

NLM ID

2985213R

Subset

External Links

PubMed source DOI: 10.1016/S0140-6736(05)61810-7 View journal details

Analysis Services

Why tyrosinase for treatment of melanoma.

Contact

WeChat Official Account